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Abstract
Background: Genetic risk factors for Alzheimer’s disease imply that inflammation plays a causal role in development of
the disease. Experimental studies suggest that microglia, as the brain macrophages, have diverse functions, with their
main role in health being to survey the brain parenchyma through highly motile processes.
Methods: Using the Medical Research Council Cognitive Function and Ageing Studies resources, we have
immunophenotyped microglia to investigate their role in dementia with Alzheimer’s pathology. Cerebral cortex
obtained at post-mortem from 299 participants was analysed by immunohistochemistry for cluster of differentiation
(CD)68 (phagocytosis), human leukocyte antigen (HLA)-DR (antigen-presenting function), ionized calcium-binding
adaptor molecule (Iba1) (microglial motility), macrophage scavenger receptor (MSR)-A (plaque-related phagocytosis)
and CD64 (immunoglobulin Fcγ receptor I).
Results: The presence of dementia was associated positively with CD68 (P < 0.001), MSR-A (P = 0.010) and CD64 (P = 0.
007) and negatively with Iba1 (P < 0.001). Among participants without dementia, the cognitive function according to
the Mini-Mental State Examination was associated positively with Iba1 (P < 0.001) and negatively with CD68 (P = 0.033),
and in participants with dementia and Alzheimer’s pathology, positively with all microglial markers except Iba1. Overall,
in participants without dementia, the relationship with Alzheimer’s pathology was negative or not significant, and
positive in participants with dementia and Alzheimer’s pathology. Apolipoprotein E (APOE) ε2 allele was associated with
expression of Iba1 (P = 0.001) and MSR-A (P < 0.001) and APOE ε4 with CD68, HLA-DR and CD64 (P < 0.001).
Conclusions: Our findings raise the possibility that in dementia with Alzheimer’s pathology, microglia lose
motility (Iba-1) necessary to support neurons. Conversely, other microglial proteins (CD68, MSR-A), the role of
which is clearance of damaged cellular material, are positively associated with Alzheimer’s pathology and
impaired cognitive function. In addition, our data imply that microglia may respond differently to Aβ and tau
in participants with and without dementia so that the microglial activity could potentially influence the
likelihood of developing dementia, as supported by genetic studies, highlighting the complexity and diversity
of microglial responses.
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Background
Genome-wide association studies have implicated several
inflammation-related genes as risk factors for Alzheimer’s
disease, particularly in relation to innate immunity, sug-
gesting a component of microglial activity is likely to be
causal in the pathogenetic pathway [1]. The genetic studies
also re-emphasized apolipoprotein E (APOE) genotype as
the main risk factor for sporadic Alzheimer’s disease [1].
Microglia are the resident tissue macrophages of the
central nervous system and thus have a key role in the im-
mune surveillance of the brain [2]. They are normally
highly motile cells with numerous long processes through
which they are constantly sensing the brain environment
for change [3]. Therefore, microglia react to any brain
pathology including neuronal and synaptic damage and
abnormal accumulations of proteins, fundamental features
of Alzheimer’s disease [2]. Since the 1990s, it has been
proposed that inflammatory processes may play an im-
portant role in the pathogenesis of Alzheimer’s disease.
Early proponents of this idea suggested that neurotoxic
substances (e.g. cytokines, complement) produced by
microglia are an important cause of neuronal damage,
which then provokes further microglial activation result-
ing in a self-perpetuating positive feedback loop [4, 5]. In
addition, ageing, the main risk factor for Alzheimer’s dis-
ease, has been identified to be associated with a more pro-
inflammatory/primed microglial state [6, 7].
Epidemiological retrospective studies also support the
“inflammation hypothesis” of Alzheimer’s disease with evi-
dence that non-steroidal anti-inflammatory drugs may be
protective against the development of Alzheimer’s disease
[8–10]. However, randomized controlled clinical trials of
anti-inflammatory drugs in large cohorts of patients
with established disease did not demonstrate benefit
[11], perhaps reflecting our lack of knowledge of the
specific roles of microglia at different stages in the
development of Alzheimer’s disease.
The development of in vivo positron emission tomog-
raphy (PET) imaging for microglia, using a ligand for
translocator protein (TSPO), a protein present on the
mitochondrial membrane and upregulated in neuroin-
flammation [12], has demonstrated microglial activation
in Alzheimer’s disease [13]; although how the radioli-
gand relates to the functional state of microglia is still
unknown.
Considerable information is available about peripheral
macrophages, to which microglia are related, which are
highly plastic cells that adapt their behaviour to their
environment undertaking different functions including
recognition of pathogens, phagocytosis of microorgan-
isms and cell debris, antigen presentation, cell toxicity
and modulation of inflammation [2]. By extrapolation,
microglia are likely to have a similar range of functions
as supported by experimental models [14, 15] and post-
mortem human studies [15, 16]. It is now recognized that
cell morphology does not provide information on micro-
glial function [2] and thus characterization of expression
of microglial proteins related to different microglial func-
tions (i.e. immunophenotyping) can offer a window into
their functional status in a given situation.
The Medical Research Council Cognitive Function and
Ageing Study (MRC CFAS) is a multi-centred community-
based study of the older population in the UK which
includes participants with a full range of cognitive function
from normal to those with dementia. The participants have
been followed for over 20 years and offered the option for
post-mortem brain donation. The result is a large cohort of
cases which are unselected on the basis of cognitive func-
tion, dementia type and treatment and characterized in
terms of clinical and neuropathological data [17, 18], allow-
ing us to test our hypothesis on an unbiased representation
of the elderly population. To test our hypothesis that differ-
ent microglial functions are related to Alzheimer’s disease,
we have immunophenotyped microglia in the CFAS cohort
using antibodies to five proteins involved in different
functions (Table 1, Fig. 1). This allowed us to assess
whether a microglial immunophenotype is associated
with (i) the presence of dementia, (ii) cognition, (iii)
Alzheimer’s pathology and whether (iv) the effect of
APOE genotype on the risk of dementia is related to
the phenotype of microglia.
Methods
The CFAS cohort
The CFAS study involves six centres in the UK (Liverpool,
Cambridge, Gwynedd, Newcastle, Nottingham and
Oxford). The design and methods have been described in
detail elsewhere [17]. In brief, the project began in the
early 1990s and recruited individuals living in the commu-
nity aged 65 years and over. The main aims were to esti-
mate the prevalence and incidence of cognitive decline
and dementia, to determine the rate of progression of cog-
nitive decline and survival and to identify risk factors for
cognitive decline and dementia. Baseline prevalence
screening of the cohort included sociodemographic, cog-
nitive and physical health data. Participants were invited
to consent to brain donation after death. The ascertain-
ment of dementia status at death has been described in
detail [18] and was based on review of information avail-
able from death certificates, last interview assessment and
the informants’ information about participants’ function
and cognition (Mini Mental State Examination (MMSE)
score) during the last years of life. The brains of 299 par-
ticipants were used in this study with the demographic
and cognitive profile of the cohort described in Table 1. In
21 cases, insufficient information was available for a diag-
nosis of dementia to be made, and thus, these cases are
excluded from the analysis.
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Assessment of Alzheimer’s pathology
We used the previous pathological evaluation of the CFAS
cohort conducted by neuropathologists, blind to clinical
data, using immunohistochemical or tinctorial methods
[18]. The severity of diffuse plaques, neuritic plaques and
tangles had been scored semi-quantitatively according to
the Consortium to Establish a Registry for Alzheimer’s
Disease (CERAD) protocol as either “none,” “mild,” “mod-
erate” or “severe” [19]. For the analysis, as the score “se-
vere” did not occur frequently, it was merged with
“moderate”, and the score “mild” was merged with “none.”
Cerebral amyloid angiopathy (CAA) was assessed in the
meninges and parenchyma on a similar semi-quantitative
scale. At the end of the assessment, a final neuropatho-
logical diagnosis of Alzheimer’s disease based on the
distribution and severity of plaques and tangles but blind
to any clinical information was made.
Immunohistochemistry
The following primary antibodies were used: rabbit
anti-human ionized calcium-binding adaptor molecule
(Iba)-1 (Wako, Osaka Japan); mouse anti-human cluster
of differentiation (CD)68 (clone PG-M1, Dako, Glostrup
Denmark); mouse anti-human human leukocyte antigen
(HLA)-DR (clone CR3-43, ThermoFisher Scientific,
Loughborough UK); goat anti-human macrophage scaven-
ger receptor (MSR)-A (R&D Systems, Abingdon UK); and
mouse anti-human CD64 (immunoglobulin Fcγ-receptor
I, R&D Systems, Abingdon UK) (Table 1, Fig. 1, Table 2).
Four micrometer sections of formalin-fixed paraffin-
embedded tissue from the middle frontal gyrus, a
region which is part of the CERAD neuropathology
assessment for the diagnosis of Alzheimer’s disease,
were used for immunostaining for microglial proteins.
Immunohistochemistry was performed using the appro-
priate antigen retrieval methods for each primary anti-
body. Biotinylated secondary antibodies were from Dako
(Glostrup, Denmark) and normal serum and avidin-biotin
complex from Vector Laboratories (Peterborough, UK).
Biotinylated antibody was visualized using the avidin-
biotin-peroxidase complex method (Vectastain Elite
ABC from Vector Laboratories (Peterborough, UK))
with 3,3′-diaminobenzidine (DAB, Vector Laboratories
(Peterborough, UK)) as chromogen and 0.05 % hydrogen
peroxide as substrate. All sections were counterstained
with haematoxylin and then dehydrated before mounting
in DePeX (VWR International, Lutterworth, UK). Cases
were immunolabelled together in batches to ensure com-
patibility of staining, and sections incubated in the
absence of the primary antibody were included as negative
controls. For each antibody, a positive control was in-
cluded to ensure staining consistency across the different
batch runs.
Quantification
Quantification was performed blind to the experimental
group and identity of the cases. Images of the slides were
taken starting from the sulcal depth adjacent to the mid-
dle frontal gyrus. For each antibody, 30 images of cor-
tical grey matter at magnification ×20 were taken per
case in a zigzag sequence along the cortical ribbon to
ensure that all cortical layers were represented in the
quantification in an unbiased manner. The acquired
images were analysed using ImageJ (version 1.49 m,
Wayne Rasband, NIH, USA), with a threshold applied to
the image to select and measure the total amount of spe-
cific immunostaining. The same threshold setting was
maintained for all images of all cases stained for the
Table 1 Known functions of microglial proteins investigated
Proteins Functions
Ionized calcium-binding
adaptor molecule (Iba)1
Cytoplasmic protein constitutively expressed by microglia, upregulated in inflammation. Iba1 is
involved in cytoskeletal reorganization, membrane ruffling of the microglial processes and actin
cross-linking needed for cell migration [23], thus reflecting microglial motility and migration properties.
CD68 CD68 labels lysosomal and endosomal transmembrane glycoprotein of microglia, indicating phagocytic
activity [33].
Human leukocyte antigen
(HLA)-DR
HLA-DR is a Major Histocompatibility Class (MHC) II cell surface receptor which presents antigens to cells of
the immune system eliciting an immune response, involved in the non-self recognition and upregulated
in inflammation [34].
Macrophage scavenger
receptor (MSR)-A
MSR-A is a lipoprotein receptor involved in direct ligand recognition and scavenging activity.
Its mouse homolog, scavenger receptor A (SR-A), is associated with plaques and release of
reactive oxygen species and neurotoxic substances by microglia upon stimulation with fibrillar
Aβ [35]. We previously showed a clustering pattern of MSR-A-positive microglia round plaques in
Alzheimer's disease [16] suggesting expression of MSR-A may cause immobilization of the microglia
when they encounter plaques [16, 26].
CD64 (Fcγ receptor I) CD64 is a cell surface receptor with high affinity for the Fc portion of immunoglobulin (IgG), triggering
a monocyte/macrophage response [30]. Expression of CD64 reflects the presence of immunoglobulins
in the brain and thus the involvement of systemic immunity [36]. Overall FcγRs are important for
antibody-dependent cytotoxicity, antigen presentation via MHC, clearance of antibodies and
phagocytosis [37].
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same antibody, and the area fraction of the measure func-
tion provided the proportion (%) of the stained area
related to the total area of the image (expressed as protein
load) [20]. A macro was designed to incorporate all the
steps allowing automatic image processing and data col-
lection. The data were then sent to the Department of
Public Health and Primary Care for statistical analysis.
Statistical analysis
The microglial data were analysed in relation to dementia
status, cognition using the MMSE score [21] as a meas-
urement of general cognition, specific pathological fea-
tures of Alzheimer’s disease and APOE genotype. The
relationships of Iba1, HLA-DR, CD68, CD64 and MSR-A
expression with the different parameters were verified
using weighted regression in which the 30 images ac-
quired for each microglial protein were given the same
1/30 weight. Weighted logistic regressions were per-
formed to verify the relationship between microglia and
the dementia status; and weighted multiple linear regres-
sion analysis to assess whether microglial expression was
related to cognition with adjustment for the gap between
last interview and death. Weighted logistic regression ana-
lysis was used to assess the extent of the relationship
between microglial expression and frontal lobe neurode-
generative pathologies. Participants with non-Alzheimer’s
dementia were excluded. To verify the association of
APOE genotype with microglial expression (dependent
variables), weighted linear regressions were performed
with ε2 and ε4 carrier status used as independent var-
iables regardless of the number of alleles and with
both alleles simultaneously present in the analysis. In
addition, all analyses were adjusted for age of death
and sex. All tests were two-tailed, and statistical ana-
lyses were performed using the statistical package
STATA, version 12. A P value <0.05 was considered
as significant.
Results
Characteristics of the cohort regarding dementia status
Among the 299 cases, 130 (47 %) cases did not have
dementia at death. From the 148 participants who devel-
oped dementia, 83 (56 %) had plaques and tangles suffi-
cient for the diagnosis of Alzheimer’s disease as the
cause of dementia, and for 21 (7 %) cases, the dementia
status was unknown. For the control group (participants
without dementia), 66 (51 %) were women, the median
age at death was 84 years (77–90) and the median
MMSE score performed at the last assessment was of 25
(22–28). For the group with dementia, 102 (69 %) were
women, including 64 % with Alzheimer’s pathology, with
median age at death of 89 years (83–93). The median
MMSE score performed at the last assessment for the
participants with dementia and without Alzheimer
Fig. 1 Illustration of microglia immunophenotyping in the human
post-mortem brain using five antibodies related to different microglial
functions. Haematoxylin counterstaining; scale bar: 30 μm
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pathology was 18 (11–23) and 11 (6–17) for people with
dementia with Alzheimer’s pathology. Education was al-
most a constant, very similar across the groups and thus
was not included as a covariate in our analysis (Table 3).
Subsequent analysis omitted the group of dementia with
non-Alzheimer’s pathology as these are a heterogeneous
group and instead focused on comparisons between the
participants with dementia and Alzheimer’s pathology
and those without dementia.
Microglia and cognition
Dementia status and a general cognitive function assess-
ment (MMSE score) were used to assess cognition. The
analyses were performed in relation to the microglial
markers and included only participants without dementia
and participants with dementia and Alzheimer’s path-
ology. Firstly, for dementia status (Table 4), there was a
significant positive relationship with CD68 (P < 0.001),
MSR-A (P = 0.010) and CD64 (P = 0.007) and a significant
negative relationship with Iba1 (P < 0.001); no significant
association was observed with HLA-DR. Thus, high loads
of CD68, MSR-A and CD64 and a low Iba1 expression
were related to the presence of dementia. Secondly, in
relation to the MMSE score (Table 5), among the partici-
pants without dementia, there was a significant positive
relationship with Iba1 (P < 0.001) and a negative
relationship with CD68 (P = 0.033); no other significant
association was observed. In the Alzheimer’s cohort, there
was a significant positive relationship of MMSE score with
CD64 (P = 0.023) and a negative relationship with CD68
(P < 0.001), MSR-A (P < 0.001) and HLA-DR (P < 0.001);
no association was observed with Iba1. This indicates that
poor cognition was related to higher expression of CD68,
MSR-A and HLA-DR and lower expression of CD64.
Overall, in both analyses (dementia and MMSE score),
good cognition was associated with higher Iba1 and lower
CD68 expression.
Microglia and Alzheimer’s neuropathology
Five neuropathological Alzheimer’s disease features previ-
ously assessed [18] were investigated in relationship with
microglia: meningeal and parenchymal CAA, diffuse and
neuritic plaques and tangles (Table 6 (A and B)). Among
participants without dementia, the significant relation-
ships observed between microglia and Alzheimer’s neuro-
pathology were mainly negative, except for diffuse plaques
which were positively related with four of the five micro-
glial markers (Iba1, CD68, HLA-DR, CD64: P < 0.001) and
Iba1 with neuritic plaques (P = 0.003) (Table 6A). The
positive association between microglial markers and dif-
fuse plaques regardless of Alzheimer’s disease is consistent
with diffuse plaques being a relatively non-specific feature
Table 2 Antibodies and conditions
Microglial protein Species Clone/company Dilution Antigen retrieval technique
Iba1 Rabbit Polyclonal/Wako 1:750 Pressure cooker citrate pH 6
CD68 Mouse PG-M1/Dako 1:50 Microwave citrate pH 6
HLA-DR Mouse CR3/43/ThermoFisher Scientific 1:200 Microwave citrate pH 6
MSR-A Goat Polyclonal/R&D Systems 1:500 Microwave citrate pH 6
CD64 Goat Polyclonal/R&D Systems 1:100 Microwave EDTA pH 8
Table 3 Characteristics of the cohort according to dementia status and microglial protein load (%)
No dementia Dementia with AD pathology Dementia non-AD pathology Unknown dementia status
(n = 130) (n = 83) (n = 65) (n = 21)
Number of womena 66 (51) 53 (64) 49 (75) 10 (48)
Age at death (years)b 84 (77; 90) 89 (83; 93) 89 (85; 93) 86 (84; 91)
Education (years)b 9 (9; 10) 9 (9; 10) 9 (9; 9) 9 (9; 9)
Years since last cognitive assessmentb 1.1 (0.5; 1.8) 1.5 (0.8; 3.2) 1.7 (0.8; 3.0) 2.5 (2.0; 3.4)
MMSE at last assessmentb 25 (22; 28) 11 (6; 17) 18 (11; 23) 25 (22; 27)
Iba1 load (%)c 2.346 (0.027) 2.047 (0.027) 1.824 (0.031) 2.372 (0.070)
CD68 load (%)c 0.090 (0.001) 0.100 (0.002) 0.088 (0.002) 0.054 (0.002)
HLA-DR load (%)c 0.213 (0.008) 0.277 (0.011) 0.143 (0.005) 0.101 (0.007)
MSR-A load (%)c 0.181 (0.003) 0.188 (0.003) 0.172 (0.003) 0.171 (0.005)
CD64 load (%)c 0.517 (0.006) 0.523 (0.007) 0.448 (0.007) 0.523 (0.013)
AD Alzheimer’s disease
an (%)
bMedian (interquartile range)
cLinearized mean (linearized standard error)
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of ageing pathology [22]. In the participants with dementia
and Alzheimer’s pathology, the significant relationships
were mainly positive and stronger than those in the partici-
pants without dementia (Table 6B). Iba1 expression was
significantly related to all neuropathological features. CD68
and MSR-A were strongly related with neuritic plaques
(P < 0.001) and tangles (P < 0.001). HLA-DR and CD64
were significantly related to all neurodegenerative path-
ologies, except for parenchymal CAA and tangles
(Table 6B).
Interestingly, only one significant relationship was
observed between cognition and the features of Alzhei-
mer's pathology which was a negative association be-
tween tangles and MMSE score in the participants
with dementia and Alzheimer’s pathology (Table 7).
Microglia and APOE genotype
We assessed the extent of the association of APOE
genotype, the main genetic risk factor for sporadic
Alzheimer’s disease, and altered microglial expression
(Table 8). We detected that the possession of an APOE
ε2 allele, known to be associated with reduced risk of
Alzheimer’s disease, was significantly related to a high
expression of Iba1 (P = 0.001) and MSR-A (P < 0.001)
and a reduced amount of CD68 and HLA-DR (P <
0.001, respectively), whereas possession of an APOE ε4
allele, known to be associated with increased risk of
Alzheimer’s disease, was significantly related to greater
expression of CD68, HLA-DR and CD64, but a reduced
amount of Iba1 (P < 0.001, respectively).
Relationship between the different types of microglial
markers
We explored the relationships between the microglial
markers and found weak but significant relationships
(r < 0.54, P < 0.015), except for CD68 and Iba1 which
were not significantly related (P = 0.332; data not
shown), supporting the hypothesis that microglial
functions are performed relatively independently [16].
Discussion
Our findings suggest that specific microglial proteins
relating to diverse functions associate differently with
cognition and features of Alzheimer’s disease pathology
and that a change in microglial status may be important
in the evolution of Alzheimer’s disease. We showed the
association of Iba1 expression with the absence of
dementia and scores of good cognition, whereas the
presence of CD68, MSR-A and HLA-DR is related to
dementia and scores of poor cognitive function. One of
the main functions of microglia is to survey the brain
parenchyma using highly motile cellular processes [3],
which are regulated by actin polymerization and inter-
action with Iba1, an actin cross-linking protein crucial
for actin bundling and microglial membrane ruffling
[23]. Our finding raises the possibility that preserved
microglial motility, being related to Iba1 expression, may
protect against neurodegeneration putatively by facilitat-
ing active surveillance of the brain environment and
rapid response towards any potentially neurotoxic insult.
In contrast, the presence of HLA-DR (involved in anti-
gen presentation and identified as a genetic risk factor
for Alzheimer’s disease [1]) and phagocytic activity
(CD68 and MSR-A) is detrimental to the brain, either by
promoting or responding to neuronal damage. The
absence of a significant relationship between cognition
and Iba1 in the dementia cohort with Alzheimer’s
pathology is consistent with the hypothesis that micro-
glia may lose their motility potentially as a result of (i)
Table 5 Weighted linear regression analyses investigating the relationship between microglial protein load (%) and the MMSE score
in participants with and without dementia
Microglia
(load (%))
No dementia Dementia with Alzheimer’s pathology
β 95 % CI (β) P β 95 % CI (β) P
Iba1 0.37 (0.29; 0.45) <0.001 −0.13 (−0.32; 0.05) 0.154
CD68 −1.54 (−2.96;−0.13) 0.033 −12.17 (−15.13; −9.21) <0.001
HLA-DR 0.18 (−0.04; 0.41) 0.116 −1.11 (−1.59; −0.64) <0.001
MSR-A −0.69 (−1.38; 0.00) 0.051 −4.94 (−6.82; −3.07) <0.001
CD64 0.27 (−0.03; 0.58) 0.076 1.08 (0.15; 2.02) 0.023
These analyses only included participants without dementia or with dementia with Alzheimer’s pathology. Significant positive association (bold); significant
negative association (italic)
Table 4 Weighted logistic regression to analyse the relationship
between microglial protein load (%) and dementia status in
participants with and without Alzheimer’s dementia
Microglia (load (%)) OR 95 % CI (OR) P
Iba1 0.86 (0.82; 0.89) <0.001
CD68 3.55 (1.93; 6.51) <0.001
HLA-DR 1.06 (0.96; 1.18) 0.250
MSR-A 1.56 (1.11; 2.19) 0.010
CD64 1.21 (1.05; 1.39) 0.007
These analyses only included participants without dementia or with dementia
with Alzheimer’s pathology. Significant positive association (bold); significant
negative association (italic)
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AD-related microglial dysfunction due to senescence
[24, 25], (ii) immobilization of microglia around pla-
ques [16, 26] and/or (iii) an immunosuppressed status
of microglia preventing them responding appropriately
to the pathological environment [15, 24, 27]. Interest-
ingly, the negative association of Iba1 with dementia
status and yet its positive association with all five
neuropathological features in established Alzheimer’s
disease are seemingly contradictory findings that merit
further exploration. These findings could be interpreted
as consistent with microglial dysfunction and/or of the
presence of an immunosuppressive environment inhi-
biting microglia from responding appropriately to the
accumulated proteins.
Remarkably, the association between microglia and
Alzheimer’s pathology appeared to change pattern
between participants without and with dementia, with
negative relationships with the different pathological fea-
tures of AD prevailing in the absence of dementia and
positive relationships in the dementia with Alzheimer’s
pathology group. A key previous finding from CFAS
neuropathology studies was that Alzheimer’s pathology
Table 7 Linear regression analyses investigating the relationship between Alzheimer’s pathology and the MMSE score in participants
with and without dementia
Alzheimer’s
pathology
No dementia Dementia with Alzheimer’s pathology
β 95 % CI (β) P β 95 % CI (β) P
Meningeal CAA 0.48 (−2.87; 3.82) 0.779 0.49 (−3.25; 4.24) 0.794
Parenchymal CAA −3.63 (−9.33; 2.07) 0.210 1.67 (−3.04; 6.39) 0.482
Diffuse plaques 0.74 (−0.67; 2.15) 0.299 0.50 (−3.45; 4.45) 0.800
Neuritic plaques 0.24 (−1.61; 2.09) 0.797 −2.43 (−5.84; 0.99) 0.161
Tangles 1.83 (−3.90; 7.56) 0.528 −4.12 (−7.60; −0.65) 0.021
These analyses only included participants without dementia or with dementia with Alzheimer’s pathology. Significant negative association (italic)
Table 6 Weighted logistic regression analyses to investigate the relationship between microglia and Alzheimer’s pathology in
participants with and without dementia
Microglia (load (%)) Meningeal CAA Parenchymal CAA Diffuse plaques Neuritic plaques Tangles
A. No dementia
Iba1 0.92 (0.84; 1.01) 0.72 (0.65; 0.79) 1.2 (1.15; 1.25) 1.07 (1.02; 1.13) 0.74 (0.68; 0.80)
0.064 <0.001 <0.001 0.003 <0.001
CD68 0.09 (0.01; 0.99) 0.00 (0.00; 0.01) 8.62 (3.83; 19.40) 0.02 (0.01; 0.07) 1.07 (0.06; 19.41)
0.049 <0.001 <0.001 <0.001 0.965
HLA-DR 0.27 (0.16; 0.47) 0.79 (0.56; 1.12) 2.24 (1.77; 2.83) 1.02 (0.91; 1.15) 0.07 (0.02; 0.25)
<0.001 0.183 <0.001 0.728 <0.001
MSR-A 0.16 (0.05; 0.47) 0.03 (0.00; 0.35) 1.42 (0.95; 2.13) 0.24 (0.14; 0.40) 0.44 (0.10; 1.96)
0.001 0.005 0.09 <0.001 0.283
CD64 1.14 (0.77; 1.69) 0.70 (0.52; 0.94) 1.86 (1.57; 2.20) 0.70 (0.58; 0.86) 0.77 (0.45; 1.32)
0.505 0.018 <0.001 0.001 0.343
B. Dementia with Alzheimer’s pathology
Iba1 1.36 (1.28; 1.45) 1.53 (1.43; 1.64) 1.37 (1.24; 1.51) 1.5 (1.40; 1.61) 1.14 (1.07; 1.21)
<0.001 <0.001 <0.001 <0.001 <0.001
CD68 1.07 (0.42; 2.73) 1.40 (0.43; 4.55) 0.17 (0.06; 0.48) 31.65 (11.54; 86.81) 49.28 (19.43; 124.99)
0.892 0.576 0.001 <0.001 <0.001
HLA-DR 0.62 (0.52; 0.74) 1.07 (0.94; 1.22) 3.22 (2.50; 4.15) 2.28 (1.65; 3.14) 1.74 (1.42; 2.13)
<0.001 0.302 <0.001 <0.001 <0.001
MSR-A 2.43 (1.26; 4.66) 2.24 (1.03; 4.84) 2.44 (1.15; 5.21) 10.31 (5.03; 21.11) 3.24 (1.74; 6.04)
0.008 0.041 0.021 <0.001 <0.001
CD64 2.15 (1.71; 2.71) 2.14 (1.63; 2.80) 21.59 (14.22; 32.78) 4.39 (3.39; 5.70) 1.27 (0.99; 1.62)
<0.001 <0.001 <0.001 <0.001 0.056
Values are presented as follows: OR (95 % CI (OR)), P. Significant positive association (bold); significant negative association (italic)
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is notably prevalent in elderly non-demented people
[22], suggesting that additional factors over and above
the plaques and tangles may be required to promote
dementia. The results of the current study suggest that
alterations in the microglial responses may, at least in
part, provide that additional factor. More specifically,
microglia seem to respond differently to Aβ and tau in
participants with and without dementia, perhaps influen-
cing the development of dementia rather than simply
being the consequence of the ongoing neurodegenera-
tion. In addition, the contention that motile microglia
respond to pathology in a protective way is also sup-
ported by the finding that in participants without
dementia, there is a negative relationship between tan-
gles and the marker Iba1 (associated with absence of
dementia and good cognition); and in the participants
with dementia and Alzheimer’s pathology by a worse
MMSE score related to tangles but not Iba1 expression.
Our analysis of MMSE score and neuropathology con-
firmed that tangles are a better marker of cognitive
impairment than Aβ plaques [28]. In the participants
with dementia and Alzheimer’s pathology, the relation-
ships between CD68, MSR-A and less strongly HLA-DR
with tau pathology (i.e. tangles and neuritic plaques) are
consistent with either microglial activity promoting or
responding to tau accumulation. The association of
CD68 with dementia, poor cognitive function and tau
pathology (i.e. neuritic plaques and tangles) is particu-
larly strong. CD68 is a protein present in phagocytic
lysosomes within the microglia; however, it is not known
whether microglia are causing harm by actively phago-
cytosing functioning neurons and synapses [29] or clear-
ing up debris from damaged neurons and therefore
simply responding to the neurodegeneration. CD64
expression is associated with the presence of dementia
but not tangles. CD64 is the only high-affinity receptor
for antibodies [30], reflecting the potential involvement
of systemic immunity in the disease process [31]. For
example, CD64 might participate in the immunosup-
pressed environment described in experimental and
human studies of Alzheimer’s disease [15, 27] and thus
to the impairment of microglial motility.
We demonstrated that APOE polymorphism may
influence the microglia towards a protective (ε2 allele)
or detrimental profile (ε4 allele), consistent with our
clinical findings and previous studies [32]. The protect-
ive ε2 allele is associated with high expression of Iba1
(absence of dementia, good cognition), while the risk ε4
allele is associated with CD68, HLA-DR and CD64
(presence of dementia and bad cognition). However,
microglia did not change the relationship between
APOE genotype and dementia (analysis not shown),
reinforcing APOE genotype as the stronger risk factor
for Alzheimer’s disease.
Conclusions
Despite the limitations inherent to any human post-mor-
tem study, the major value of studying the human brain
in this way is that it is a study of the disease itself rather
than an experimental model of some aspect of the dis-
ease which does not inform specifically on human
microglia. The novelty of our study resides in the com-
bination of several microglial markers with known func-
tions to investigate the role of microglia in Alzheimer’s
disease in an unbiased population using a defined set of
clinical and neuropathological parameters. Immunophe-
notyping microglia has demonstrated a weak relation-
ship between the different microglial proteins studied
revealing that (i) expression by microglia of one of the
proteins does not necessarily predict the expression of
the other proteins supporting the concept that microglia
are able to adopt different functions relatively independ-
ently but also (ii) that different microglial populations
may coexist within the brain as supported by the ab-
sence of association between CD68 and Iba1.
The complexity of microglial responses in the human
brain as demonstrated in our study is important to
reflect on, as this may explain the failure of anti-
inflammatory agents in Alzheimer’s disease clinical trials
and is likely to be a key to developing suitably tailored
anti-inflammatory therapy to protect the ageing brain
against neurodegeneration. Secondly, microglial activa-
tion can now be visualized and quantified in vivo with
PET scans using specific ligands (e.g. TSPO). This tech-
nology is becoming widely used in different neurode-
generative diseases with an inflammatory component
and in clinical trials to follow the effects of the drugs.
Therefore, our findings highlight the importance of the
phenotype expressed by microglia on the disease
Table 8 Weighted linear regression analyses to investigate the
association of APOE genotype with microglia
Microglia (load (%)) β 95 % CI (β) P
ε2
Iba1 0.156 (0.068; 0.244) 0.001
CD68 −0.010 (−0.014; −0.005) <0.001
HLA-DR −0.036 (−0.055; −0.017) <0.001
MSR-A 0.017 (0.008; 0.026) <0.001
CD64 0.020 (−0.001; 0.040) 0.060
ε4
Iba1 −0.166 (−0.237; −0.096) <0.001
CD68 0.015 (0.011; 0.019) <0.001
HLA-DR 0.042 (0.019; 0.065) <0.001
MSR-A −0.004 (−0.010; 0.003) 0.317
CD64 0.041 (0.024; 0.058) <0.001
Significant positive association (bold); significant negative association (italic)
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progression, an important parameter to consider when
interpreting data from PET imaging for microglia, as
one ligand is unlikely to reflect all aspects of microglial
function [12, 13].
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